^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Malignant Pleural Mesothelioma

    Related cancers:
    5d
    Dynamic Evaluation Of The Glycolytic Determinants LDH-A And GLUT-1 Enhances Prognostic Significance And Their Inhibition Affect The Growth Of Mesothelioma Spheroids. (PubMed, Mol Metab)
    Overexpression and chemotherapy-induced modulation of LDH-A and GLUT-1 correlated with poor MM prognosis. Combined inhibition of these two metabolic determinants impeded MM cell migration, stimulated ROS production and apoptosis, and affected spheroids' growth, offering promise for new treatment development.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SLC2A1 (Solute Carrier Family 2 Member 1)
    6d
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=257, Recruiting, AstraZeneca | N=110 --> 257
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)
    11d
    Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival. (PubMed, JCO Precis Oncol)
    Young patients with DPM have strong personal and family histories of cancer, and heterogeneous somatic and germline alterations, indicating divergent underlying biology. With the increasing prevalence of young adults with cancers, mesotheliomas, although uncommon, should be on the differential for patients even without asbestos exposure history in this age group.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    TMB-L
    15d
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9th Edition Staging Database. (PubMed, J Thorac Oncol)
    In this large PM cohort,CDKN2A, NF2, and TP53 alterations were associated with worse OS, while BAP1 alterations were associated with better prognosis, independent of clinical variables and histology. Modeling suggests that genomic alterations provide additional prognostic information beyond anatomic TNM and clinicopathologic features.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1)
    |
    PD-L1 expression
    17d
    TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma. (PubMed, Int J Mol Sci)
    Data obtained clearly highlighted how TGF-β inhibition, through the silencing or treatment of MPM cells with antibody anti-TGF-β (Fresolimumab), significantly reduces cell proliferation (MTT, PCNA) and prevents metastasis, reducing EMT and decreasing the invasiveness and migration of MPM cells...Taken as a whole, targeting TGF-β will represent a starting point for future improvements in MPM management. This is particularly important as we foresee a growing increase in MPM in the coming years.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PCNA (Proliferating cell nuclear antigen)
    |
    fresolimumab (GC 1008)
    18d
    A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=14 --> 7
    Enrollment closed • Enrollment change
    |
    Keytruda (pembrolizumab)
    19d
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Feb 2027
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343)
    24d
    Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028
    Trial completion date
    |
    Keytruda (pembrolizumab)
    25d
    Short Neoadjuvant Hemithoracic IMRT for MPM (clinicaltrials.gov)
    P1/2, N=104, Completed, University Health Network, Toronto | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Sep 2025 | Trial primary completion date: Sep 2027 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin
    26d
    From Presentation to Diagnosis: Patterns of Pleural Effusion (clinicaltrials.gov)
    P=N/A, N=300, Completed, Mansoura University Hospital
    New trial
    28d
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New P1 trial • First-in-human
    |
    Proleukin (aldesleukin)
    30d
    Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma. (PubMed, Cell Death Dis)
    Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective antiproliferative properties against NF2/CDKN2A(p16)-deficient PM cells, surpassing the effects of C75, cisplatin or pemetrexed. These findings suggest that FASN might play a role in the tumorigenesis of PM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for PM.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FASN (Fatty acid synthase)
    |
    cisplatin • pemetrexed • cerulenin